Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SectorWatch.biz Releases Wind Energy Report for Investors
http://ih.advfn.com/p.php?pid=nmona&cb=1234358899&article=36201266&symbol=NB^NCEN
SectorWatch.biz Releases Wind Energy Report for Investors in Companies NCEN, TRN, KDN, OC, AMN and TNB
IRVINE, Calif., Feb. 11 /PRNewswire/ -- Investors in leading wind energy companies including Trinity Industries, Inc. (NYSE:TRN), Kaydon Corporation (NYSE:KDN), Owens Corning (NYSE:OC), Ameron International Corporation (NYSE: AMN), and Thomas & Betts Corp. (NYSE:TNB) should view a report released by StockUpTicks.com. The report examines the wind industry and the efforts of Nacel Energy Inc. (OTC:NCEN) (BULLETIN BOARD: NCEN) in executing their business plan.
The report can be accessed directly at: http://www.stockupticks.com/profiles/2-10-09.html
From the report:
Currently, America harnesses more than 21,000 MW of electric energy from wind; enough to meet the needs of 5.5 million average homes. And, according to a Department of Energy report, wind can provide much more...as much as 20% of America's energy needs by 2030.
Why wind energy? Wind energy produces no emissions and does not pollute our air or water and unlike nuclear power, requires no hazardous waste storage. Both coal (a heavy polluter) and natural gas release greenhouse gases that also may affect our world's climate. An increasingly important economic and strategic benefit of wind energy is its contribution to reducing our dependence on imported energy from less secure regions across the globe. Nacel Energy is engaged in the business of generating clean, profitable, renewable energy from wind.
For more information visit Nacel Energy's website http://www.nacelenergy.com/
Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SectorWatch.biz is property of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience. The subject companies have not always approved the statements made in this report. This report is neither a solicitation to buy nor an offer to sell securities but is for information purposes only and should not be used as the basis for any investment decision. J.A. Knepp CRD#2849651. MP isn't an investment advisor, analyst or licensed broker dealer and this report isn't investment advice. MP has been paid $10,000 by Before the Bell Publishing LLC for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in communication regarding the subject company.
Contact: Kurt Divich, Editor Market Pathways /SectorWatch.biz 702-396-1000
DATASOURCE: SectorWatch.biz
CONTACT: Kurt Divich, Editor of Market Pathways /SectorWatch.biz,
+1-702-396-1000
Web Site: http://stockupticks.com/
Short Quote™ -
http://shortsqueeze.com/?symbol=rz&submit=Short+Quote%99
Raser TechnologiesInc. $ 4.35
Short Interest (Shares Short) 8,125,500
Days To Cover (Short Interest Ratio) 23.6
Short Percent of Float 20.23 %
Short Interest - Prior 8,038,000
Short % Increase / Decrease 1.09 %
Short Squeeze Ranking™ -253
% From 52-Wk High ($ 11.79 ) -171.03 %
% From 52-Wk Low ($ 2.15 ) 50.57 %
% From 200-Day MA ($ 5.38 ) -23.68 %
% From 50-Day MA ($ 3.84 ) 11.72 %
Price % Change (52-Week) -53.00 %
Shares Float 40,170,000
Total Shares Outstanding 59,124,305
% Owned by Insiders 39.59 %
% Owned by Institutions 24.90 %
Market Cap. $ 257,190,727
Trading Volume - Today 274,823
Trading Volume - Average 345,000
Trading Volume - Today vs. Average 79.66 %
Earnings Per Share -0.44
PE Ratio
Record Date 2009-FebA
Sector Industrial Goods
Industry Industrial Electrical Equipment
Exchange NY
CHANGING ENERGIES MEANS CHANGING COSTS
Sunday, February 08, 2009
http://newenergynews.blogspot.com/2009/02/changing-energies-means-changing-costs.html
...CTIC has been halted!
http://www.nasdaqtrader.com/Trader.aspx?id=Tradehalts
CTIC and IDIS Announce Agreement for Pixantrone
http://ih.advfn.com/p.php?pid=nmona&cb=1234253549&article=36171585&symbol=N^CTIC
Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
SEATTLE, Feb. 10 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (NASDAQ and MTA: CTIC) today announced that they have executed a definitive collaborative agreement with IDIS to manage its investigational drug pixantrone on a named patient basis in Europe. Pixantrone will be supplied by IDIS to healthcare professionals for the treatment of individual patients with relapsing aggressive non-Hodgkin's lymphoma. This program is expected to be initiated by second quarter of 2009.
"Under the named patient program, CTI will be able to provide pixantrone to European patients in need at the prescriber's request while moving it through the approval process in the United States," noted Craig Philips, President of CTI. "With the announcement of preliminary results showing significantly higher rate of complete remission and improvement in progression-free survival for patients receiving pixantrone compared to standard chemotherapeutic agents, we expect to receive a number of requests for pixantrone to treat specific patients."
"Pixantrone is an important new treatment with impressive remission and progression-free survival data," said Dr. Raul Herbrecht of Strasbourg University Hospital in France. "This drug is also important because it meets an unmet medical need for this group of patients. I have been impressed by the good tolerance and efficacy of pixantrone since the first clinical trial we had with this drug in our department. We obtained excellent results in salvage therapy of non-Hodgkin's lymphoma in heavily pretreated patients and several years later some of our patients are still in complete response. These positive results have been confirmed in further studies," Dr Herbrecht added.
The EXTEND clinical trial was a phase III single-agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician.
"We are pleased to be working with Cell Therapeutics to ensure that those patients with non-Hodgkin's Lymphoma who do not respond to current available therapies have access to pixantrone through a named patient program," said Natalie Douglas, CEO, IDIS. "CTI's potentially life-saving medicine can offer these patients renewed hope for remission. We are deeply committed to work in partnership with pharmaceutical and biotechnology companies to give physicians and their patients access to new and innovative medicines through regulated and responsible channels."
CTI announced in November 2008 that it had achieved the primary efficacy endpoint of its phase III EXTEND (PIX301) trial of pixantrone (BBR2778). Patients randomized to treatment with pixantrone achieved a high rate of confirmed and unconfirmed complete remissions compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission compared to 8/70 (11%) of pixantrone recipients. Pixantrone treatment also significantly increased the overall response rate (CR/CRu+PR) with (26/70 (37.1%) for pixantrone arm compared to 10/70 (14.3%) for the control arm, p = 0.003). In January, 2009 CTI announced preliminary results that show patients treated with pixantrone experienced a statistically significant improvement in median progression-free survival, compared with other single-agent chemotherapeutic agents (4.7 months vs. 2.6 months, hazard ratio = 0.6; p = 0.0074, pixantrone vs. standard chemotherapy) based on an intent to treat analysis. PFS, CR/CRu and ORR were determined by an independent assessment panel that was blinded to the treatment assignments.
The most common serious toxicities (>5%) seen in previous trials of pixantrone include grade 3 and 4 neutropenia and febrile neutropenia. Complete safety information is not yet available for the study, however, the study was monitored on an ongoing basis by an independent Data Safety Monitoring Committee and no serious concerns were raised.
The study received Special Protocol Assessment approval from the U.S. Food and Drug Administration (FDA) in 2004 and pixantrone has received fast track designation for this indication.
About Pixantrone
Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scientists in Bresso, Italy. Pixantrone is a novel DNA major groove binder that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. Anthracyclines have been shown to be very active clinically in a number of tumor types, such as lymphoma, leukemia, and breast cancer. For these diseases, anthracycline-containing chemotherapy regimens are effective in first-line (initial) treatment. However, they may cause cumulative heart damage that limits lifetime dosage and does not allow for retreatment. Pixantrone has been designed to reduce the potential for heart damage compared to currently available anthracyclines or anthracenediones without a loss in anti-tumor or immunomodulatory activities.
About IDIS
IDIS is the world leader in the development and implementation of named patient programs and has a proven track record of working in strategic partnership with US-based companies to bring new drugs to Europe for the first time. IDIS supports customers in over 100 countries, supplying more than 400 different medicines per month and responding to more than half a million requests on a named patient basis to medical professionals worldwide. For more information on IDIS please visit our website at http://www.idispharma.com/.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/.
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the results of complete safety information, the ability of the company to initiate named patient sales by the second quarter of 2009, the failure to receive anticipated number of requests for pixantrone to treat specific patients, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, the company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
Media Contact: Dan Eramian T: 206.272.4343 C: 206.854.1200 E: http://www.celltherapeutics.com/press_room
Investors Contact: Ed Bell T: 206.272.4345 Lindsey Jesch Logan T: 206.272.4347 F: 206.272.4434 E: http://www.celltherapeutics.com/investors
DATASOURCE: Cell Therapeutics, Inc.
CONTACT: Media, Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200,
, or Investors, Ed Bell, +1-206-272-4345, or Lindsey Jesch
Logan, +1-206-272-4347, fax, +1-206-272-4434, , all of
Cell Therapeutics, Inc
Web Site: http://www.celltherapeutics.com/
CTIC and IDIS Announce Agreement for Pixantrone
http://ih.advfn.com/p.php?pid=nmona&cb=1234253549&article=36171585&symbol=N^CTIC
Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
SEATTLE, Feb. 10 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (NASDAQ and MTA: CTIC) today announced that they have executed a definitive collaborative agreement with IDIS to manage its investigational drug pixantrone on a named patient basis in Europe. Pixantrone will be supplied by IDIS to healthcare professionals for the treatment of individual patients with relapsing aggressive non-Hodgkin's lymphoma. This program is expected to be initiated by second quarter of 2009.
"Under the named patient program, CTI will be able to provide pixantrone to European patients in need at the prescriber's request while moving it through the approval process in the United States," noted Craig Philips, President of CTI. "With the announcement of preliminary results showing significantly higher rate of complete remission and improvement in progression-free survival for patients receiving pixantrone compared to standard chemotherapeutic agents, we expect to receive a number of requests for pixantrone to treat specific patients."
"Pixantrone is an important new treatment with impressive remission and progression-free survival data," said Dr. Raul Herbrecht of Strasbourg University Hospital in France. "This drug is also important because it meets an unmet medical need for this group of patients. I have been impressed by the good tolerance and efficacy of pixantrone since the first clinical trial we had with this drug in our department. We obtained excellent results in salvage therapy of non-Hodgkin's lymphoma in heavily pretreated patients and several years later some of our patients are still in complete response. These positive results have been confirmed in further studies," Dr Herbrecht added.
The EXTEND clinical trial was a phase III single-agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician.
"We are pleased to be working with Cell Therapeutics to ensure that those patients with non-Hodgkin's Lymphoma who do not respond to current available therapies have access to pixantrone through a named patient program," said Natalie Douglas, CEO, IDIS. "CTI's potentially life-saving medicine can offer these patients renewed hope for remission. We are deeply committed to work in partnership with pharmaceutical and biotechnology companies to give physicians and their patients access to new and innovative medicines through regulated and responsible channels."
CTI announced in November 2008 that it had achieved the primary efficacy endpoint of its phase III EXTEND (PIX301) trial of pixantrone (BBR2778). Patients randomized to treatment with pixantrone achieved a high rate of confirmed and unconfirmed complete remissions compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission compared to 8/70 (11%) of pixantrone recipients. Pixantrone treatment also significantly increased the overall response rate (CR/CRu+PR) with (26/70 (37.1%) for pixantrone arm compared to 10/70 (14.3%) for the control arm, p = 0.003). In January, 2009 CTI announced preliminary results that show patients treated with pixantrone experienced a statistically significant improvement in median progression-free survival, compared with other single-agent chemotherapeutic agents (4.7 months vs. 2.6 months, hazard ratio = 0.6; p = 0.0074, pixantrone vs. standard chemotherapy) based on an intent to treat analysis. PFS, CR/CRu and ORR were determined by an independent assessment panel that was blinded to the treatment assignments.
The most common serious toxicities (>5%) seen in previous trials of pixantrone include grade 3 and 4 neutropenia and febrile neutropenia. Complete safety information is not yet available for the study, however, the study was monitored on an ongoing basis by an independent Data Safety Monitoring Committee and no serious concerns were raised.
The study received Special Protocol Assessment approval from the U.S. Food and Drug Administration (FDA) in 2004 and pixantrone has received fast track designation for this indication.
About Pixantrone
Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scientists in Bresso, Italy. Pixantrone is a novel DNA major groove binder that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. Anthracyclines have been shown to be very active clinically in a number of tumor types, such as lymphoma, leukemia, and breast cancer. For these diseases, anthracycline-containing chemotherapy regimens are effective in first-line (initial) treatment. However, they may cause cumulative heart damage that limits lifetime dosage and does not allow for retreatment. Pixantrone has been designed to reduce the potential for heart damage compared to currently available anthracyclines or anthracenediones without a loss in anti-tumor or immunomodulatory activities.
About IDIS
IDIS is the world leader in the development and implementation of named patient programs and has a proven track record of working in strategic partnership with US-based companies to bring new drugs to Europe for the first time. IDIS supports customers in over 100 countries, supplying more than 400 different medicines per month and responding to more than half a million requests on a named patient basis to medical professionals worldwide. For more information on IDIS please visit our website at http://www.idispharma.com/.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/.
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the results of complete safety information, the ability of the company to initiate named patient sales by the second quarter of 2009, the failure to receive anticipated number of requests for pixantrone to treat specific patients, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, the company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
Media Contact: Dan Eramian T: 206.272.4343 C: 206.854.1200 E: http://www.celltherapeutics.com/press_room
Investors Contact: Ed Bell T: 206.272.4345 Lindsey Jesch Logan T: 206.272.4347 F: 206.272.4434 E: http://www.celltherapeutics.com/investors
DATASOURCE: Cell Therapeutics, Inc.
CONTACT: Media, Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200,
, or Investors, Ed Bell, +1-206-272-4345, or Lindsey Jesch
Logan, +1-206-272-4347, fax, +1-206-272-4434, , all of
Cell Therapeutics, Inc
Web Site: http://www.celltherapeutics.com/
...added as an assistant for now (asked IH Admin) and revise the next days ibox...
(moderator sleeps and doesn't worry about this Thread!)
;0) -
running...
CETV -
BUSINESS SUMMARY
Central European Media Enterprises, Ltd., together with its subsidiaries, invests in, develops, and operates commercial television channels in the central and eastern Europe. It operates various television channels, including NOVA TV in Croatia; PRO TV, ACASA, PRO CINEMA, SPORT.RO, MTV ROMANIA, and PRO TV INTERNATIONAL in Romania; TV MARKIZA in the Slovak Republic ; POP TV and KANAL A in Slovenia; and STUDIO 1+1, KINO, and CITI in Ukraine. It also operates TV NOVA, a television channel; and cable/satellite channels, including GALAXIE SPORT and NOVA CINEMA in the Czech Republic. The company, through its channels, broadcasts various programs, such as movies, series and documentaries, sitcoms, news, soap operas, entertainment programs and sports highlights, game shows, police series, telenovellas, and talk shows. Central European Media Enterprises was founded in 1994 and is based in Hamilton, Bermuda.
http://www.shortsqueeze.com/?symbol=cetv&submit=Short+Quote%99
Central European Media Enterprises Ltd. $ 9.58
CETV 1.37
Short Interest (Shares Short) 3,010,500
Days To Cover (Short Interest Ratio) 5.5
Short Percent of Float 12.50 %
Short Interest - Prior 4,428,400
Short % Increase / Decrease -32.02 %
Short Squeeze Ranking™ -63
% From 52-Wk High ($ 110.00 ) -1048.23 %
% From 52-Wk Low ($ 7.64 ) 20.25 %
% From 200-Day MA ($ 41.34 ) -331.52 %
% From 50-Day MA ($ 16.25 ) -69.62 %
Price % Change (52-Week) -91.20 %
Shares Float 24,090,000
Total Shares Outstanding 42,337,112
% Owned by Insiders %
% Owned by Institutions %
Market Cap. $ 405,585,299
Trading Volume - Today 561,152
Trading Volume - Average 548,400
Trading Volume - Today vs. Average 102.33 %
Earnings Per Share 3.33
PE Ratio 2.50
Record Date 2009-JanB
Sector Services
Industry Broadcasting - TV
Exchange NAS
...attacks $3
...looks good!
is this a GNPH-day (week, month)??
Ahead of the Bell: Hartford Financial shares rise
http://finance.yahoo.com/news/Ahead-of-the-Bell-Hartford-apf-14292507.html
CTIC BIO CEO Presentation to be Webcast
http://ih.advfn.com/p.php?pid=nmona&cb=1234161308&article=36153369&symbol=N^CTIC
Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast
SEATTLE, Feb. 9 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management's presentation at the 11th Annual BIO CEO & Investor Conference on Tuesday, February 10th at 9:30 AM Eastern will be webcast live with slides at http://www.celltherapeutics.com/.
The presentation will take place in the Jade Room at the Waldorf-Astoria Hotel, and will also be available for replay after the presentation.
BIO CEO & Investor Conference CTI Presentation: Tuesday, February 10, 2009 9:30 AM Eastern/3:30 PM Central European/6:30 AM Pacific Jade Room, Waldorf-Astoria Hotel Audio webcast with slides at http://www.celltherapeutics.com/
Media Contact: Cell Therapeutics, Inc.
Dan Eramian T: 206.272.4343 F: 206.272.4434 E: http://www.celltherapeutics.com/press_room
Investors Contact: Cell Therapeutics, Inc.
Ed Bell T: 206.272.4345 Lindsey Jesch Logan T: 206.272.4347 F: 206.272.4434 E: http://www.celltherapeutics.com/investors
DATASOURCE: Cell Therapeutics, Inc.
CONTACT: Media, Dan Eramian, +1-206-272-4343, fax, +1-206-272-4434,
, or Investors, Ed Bell, +1-206-272-4345, or Lindsey Jesch
Logan, +1-206-272-4347, fax, +1-206-272-4434, , all of
Cell Therapeutics, Inc.
Web site: http://www.celltherapeutics.com/
Nacel Energy Corp (NCEN / OTCBB )
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=34918947
@ f5574dm -
...please insert me as an assistant
or retires as moderator so I can take over!
Faithfully ax
nothing happen so far:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=34919148
@ TheInvisibleHand
...cann't answer to PM - "free member"
will register again to your email-list (info_ax.......)
GN from Germany ax
Thought/Opinions on ACAS ??
BUSINESS SUMMARY
American Capital, Ltd., formerly known as American Capital Strategies, Ltd., is a principal investment firm specializing in management and employee private equity buyouts, acquisitions, recapitalizations, mergers and acquisition, add-on acquisitions, securitizations, special situations, growth capital investments in middle market companies, early stage in mature private and public companies, corporate divestitures, acquisitions of portfolio companies of private equity firms, acquisitions of family-owned or closely held businesses, change of control, or the exit of minority shareholders, going private transactions, and ownership transitions. The Special Situations Group invests in troubled and distressed situations including operational turnarounds, auctions, corporate and orphan carve-outs, portfolio add-ons, complex management buyouts and provides financings for DIP, exit, mezzanine for sponsored buyouts, second lien refinance, and direct lending to distressed companies. It prefers to invest in manufacturing, services, and distribution companies. The firm also makes investments in companies that provide services or products to federal, state, or local governments, focusing on information technology for custom information technology solutions, technology and software enabling headcount reduction, technology and software enabling cost reductions in conducting transactions with or within government. American Capital, Ltd. was founded in 1986 and is based in Bethesda, Maryland
****************************************************************
http://www.shortsqueeze.com/?symbol=acas&submit=Short+Quote%99
American Capital Ltd. $ 2.73
ACAS 0.25
Short Interest (Shares Short) 32,363,700
Days To Cover (Short Interest Ratio) 4.6
Short Percent of Float 15.93 %
Short Interest - Prior 32,710,600
Short % Increase / Decrease -1.06 %
Short Squeeze Ranking™ -68
% From 52-Wk High ($ 37.85 ) -1286.63 %
% From 52-Wk Low ($ 2.24 ) 17.95 %
% From 200-Day MA ($ 12.95 ) -374.36 %
% From 50-Day MA ($ 3.93 ) -43.96 %
Price % Change (52-Week) -92.70 %
Shares Float 203,150,000
Total Shares Outstanding 206,753,532
% Owned by Insiders 1.50 %
% Owned by Institutions 37.50 %
Market Cap. $ 564,437,142
Trading Volume - Today 4,373,708
Trading Volume - Average 7,081,400
Trading Volume - Today vs. Average 61.76 %
Earnings Per Share -8.67
PE Ratio
Record Date 2009-JanB
Sector Financial
Industry Closed-End Fund - Debt
Exchange NAS
Thought/Opinions on ACAS ??
BUSINESS SUMMARY
American Capital, Ltd., formerly known as American Capital Strategies, Ltd., is a principal investment firm specializing in management and employee private equity buyouts, acquisitions, recapitalizations, mergers and acquisition, add-on acquisitions, securitizations, special situations, growth capital investments in middle market companies, early stage in mature private and public companies, corporate divestitures, acquisitions of portfolio companies of private equity firms, acquisitions of family-owned or closely held businesses, change of control, or the exit of minority shareholders, going private transactions, and ownership transitions. The Special Situations Group invests in troubled and distressed situations including operational turnarounds, auctions, corporate and orphan carve-outs, portfolio add-ons, complex management buyouts and provides financings for DIP, exit, mezzanine for sponsored buyouts, second lien refinance, and direct lending to distressed companies. It prefers to invest in manufacturing, services, and distribution companies. The firm also makes investments in companies that provide services or products to federal, state, or local governments, focusing on information technology for custom information technology solutions, technology and software enabling headcount reduction, technology and software enabling cost reductions in conducting transactions with or within government. American Capital, Ltd. was founded in 1986 and is based in Bethesda, Maryland
****************************************************************
http://www.shortsqueeze.com/?symbol=acas&submit=Short+Quote%99
American Capital Ltd. $ 2.73
ACAS 0.25
Short Interest (Shares Short) 32,363,700
Days To Cover (Short Interest Ratio) 4.6
Short Percent of Float 15.93 %
Short Interest - Prior 32,710,600
Short % Increase / Decrease -1.06 %
Short Squeeze Ranking™ -68
% From 52-Wk High ($ 37.85 ) -1286.63 %
% From 52-Wk Low ($ 2.24 ) 17.95 %
% From 200-Day MA ($ 12.95 ) -374.36 %
% From 50-Day MA ($ 3.93 ) -43.96 %
Price % Change (52-Week) -92.70 %
Shares Float 203,150,000
Total Shares Outstanding 206,753,532
% Owned by Insiders 1.50 %
% Owned by Institutions 37.50 %
Market Cap. $ 564,437,142
Trading Volume - Today 4,373,708
Trading Volume - Average 7,081,400
Trading Volume - Today vs. Average 61.76 %
Earnings Per Share -8.67
PE Ratio
Record Date 2009-JanB
Sector Financial
Industry Closed-End Fund - Debt
Exchange NAS
Thought on ACAS ??
BUSINESS SUMMARY
American Capital, Ltd., formerly known as American Capital Strategies, Ltd., is a principal investment firm specializing in management and employee private equity buyouts, acquisitions, recapitalizations, mergers and acquisition, add-on acquisitions, securitizations, special situations, growth capital investments in middle market companies, early stage in mature private and public companies, corporate divestitures, acquisitions of portfolio companies of private equity firms, acquisitions of family-owned or closely held businesses, change of control, or the exit of minority shareholders, going private transactions, and ownership transitions. The Special Situations Group invests in troubled and distressed situations including operational turnarounds, auctions, corporate and orphan carve-outs, portfolio add-ons, complex management buyouts and provides financings for DIP, exit, mezzanine for sponsored buyouts, second lien refinance, and direct lending to distressed companies. It prefers to invest in manufacturing, services, and distribution companies. The firm also makes investments in companies that provide services or products to federal, state, or local governments, focusing on information technology for custom information technology solutions, technology and software enabling headcount reduction, technology and software enabling cost reductions in conducting transactions with or within government. American Capital, Ltd. was founded in 1986 and is based in Bethesda, Maryland
****************************************************************
http://www.shortsqueeze.com/?symbol=acas&submit=Short+Quote%99
American Capital Ltd. $ 2.73
ACAS 0.25
Short Interest (Shares Short) 32,363,700
Days To Cover (Short Interest Ratio) 4.6
Short Percent of Float 15.93 %
Short Interest - Prior 32,710,600
Short % Increase / Decrease -1.06 %
Short Squeeze Ranking™ -68
% From 52-Wk High ($ 37.85 ) -1286.63 %
% From 52-Wk Low ($ 2.24 ) 17.95 %
% From 200-Day MA ($ 12.95 ) -374.36 %
% From 50-Day MA ($ 3.93 ) -43.96 %
Price % Change (52-Week) -92.70 %
Shares Float 203,150,000
Total Shares Outstanding 206,753,532
% Owned by Insiders 1.50 %
% Owned by Institutions 37.50 %
Market Cap. $ 564,437,142
Trading Volume - Today 4,373,708
Trading Volume - Average 7,081,400
Trading Volume - Today vs. Average 61.76 %
Earnings Per Share -8.67
PE Ratio
Record Date 2009-JanB
Sector Financial
Industry Closed-End Fund - Debt
Exchange NAS
Star Analysts (PWAV) -
http://finance.yahoo.com/q/sa?s=pwav
XL Capital: Short Interest Poised to Drop, Will the Stock Pop?
by: John Appel February 06, 2009
http://seekingalpha.com/article/119013-xl-capital-short-interest-poised-to-drop-will-the-stock-pop?source=feed
The Hartford: Hedged Against Disaster
http://www.smartmoney.com/investing/stocks/the-hartford-hedged-against-disaster/?cid=1122
...Certainly, the Hartford's shares aren't riskless. The insurer's normalized earnings power of around $10 a share will remain tantalizingly beyond reach for at least several years without a startling rally in both the U.S. stock and bond markets. But the battered shares could double or even triple in the interim...
The Hartford: Hedged Against Disaster
Published February 5, 2009
WANT TO MAKE A LEVERED BET on a recovery in the bond market? For those willing to take some risk, there are few better bets than buying the stock of Hartford Financial Services Group .
Hartford's stock has been trampled in the past four months, plunging from more than 60 to a low of just over 4 in late November, largely as a result of unrealized losses on bonds in the $89 billion general account that backs its life-insurance and property-and-casualty policies. Its shares have since limped back to around 13.
As risk spreads soared and its mark-to-market bond prices dropped in the fall, Hartford saw its unrealized gross bond losses jump from $700 million on Dec. 31, 2007, to $11.6 billion as of the end of October, the latest month for which figures have been disclosed. (The numbers were reported at the company's December Investor Day meeting.)
Largely as a result of these losses -- which are theoretical unless the bonds are actually sold -- the big insurer's net worth, under generally accepted accounting principles (GAAP), crumpled to $12.6 billion. That gave the company a book value of $41.80 a share at the end of September, down from $19.2 billion, or $61.20 a share at the end of 2007. Moreover, book value is believed to have slid further as a result of the bond mayhem in the fourth quarter; it now could be about $30 a share. The company will release fourth-quarter earnings this week.
Even with all of this, the Hartford, as the company is known, seems to be a compelling buy. That is our conclusion after closely inspecting information released by company executives at the December Investor Day. (Hartford Financial officials were unavailable for comment last week because of a quiet period before this Thursday's scheduled profit report.) Among other things, the insurer's executives talked of a springback potential in book value once bond prices recover from current panic levels.
The Hartford's bond holdings are largely of high quality, with a negligible default risk. As for impairment risk, company officials have put that at less than 15% of its $11.6 billion unrealized loss portfolio, even under severe economic conditions. And if it were necessary to take charges on these securities, they would be incurred over several years.
A return to more normal conditions in the bond market won't boost Hartford's net worth back to year-end 2007's $61.20 a share. The company has had to take too many earnings write-downs in the past three quarters, including $3.5 billion in after-tax asset-impairment charges and a charge of nearly $1 billion resulting from a shortfall in the expected results of its variable-annuity business, owing to stock-market declines. Offsetting these negatives somewhat was a largely undilutive $2.5 billion infusion of new capital into Hartford by Allianz (ALV.Germany) in October. In return, the German insurer got debt and preferred shares.
Yet a return in book value to $50 a share in the next year or two is possible, particularly if Washington's push to boost the capital coursing through U.S. financial markets and bolster asset prices finally bears fruit. Likewise, earnings should stabilize after a horrid third-quarter loss of $2.6 billion, largely the result of bond- and stock-market losses hitting life-insurance results and Hurricane Ike hurting property-and-casualty earnings.
MORGAN STANLEY ANALYST NIGEL DAILY foresees Hartford Financial generating operating earnings of $5.40 a share in 2009 and $5.95 in 2010. His estimates are below the consensus forecasts, which contain a lot of stale assumptions. Nonetheless, Daily indicated in a recent report, the stock looks dirt cheap, and he later raised his one-year price target to 25. Based on his 2009 estimate, Hartford trades at a price-to-earnings ratio of just under 2.5 times. And the stock fetches less than half our conservative year-end book-value estimate of $30 a share.
The Morgan Stanley analyst further asserts that, when the equity and credit markets improve, Hartford's P/E multiple could jump. Historically, the Connecticut-based insurer has traded at an average of 10 times earnings and 1.4 times book value. If it gained back most of that valuation, shares could be changing hands in the 40s. In fact, that price could be attained in a year, assuming that the company incurs no more major earnings charges. A return of book value to 50 in the next year or two could send the shares even higher. One shouldn't forget that the Hartford traded at nearly 100 just 13 months ago.
In December, Hartford Financial officials insisted that the capital-depleting $11.6 billion in mark-to-market hits that they had been forced to take for 2008's first 10 months were largely a function of illiquidity and panic in the credit markets, rather than any fundamental problems with their investment portfolio. For example, the current prices of commercial mortgage-backed securities imply a 70% decline in commercial real-estate values and a default rate more than seven times as great as any sustained during the other commercial real-estate busts of the past 25 years. Hartford Financial has $11.2 billion, or 13%, of its portfolio in commercial mortgage-backed securities (CMBS). At the same time, the valuation gap between corporate bonds and U.S. Treasuries has become a canyon. It is so wide that the implied cumulative losses on, say, triple-B corporates range from 25% to 30%, versus actual cumulative losses around 5% during the five worst years of the Great Depression. Corporate debt accounts for 33%, or $30 billion, of the Hartford's investments.
Adding to the perceived weakness has been the company's rigor in taking permanent securities charge-offs, after subjecting its unrealized-loss portfolio to tough tests. Unlike unrealized losses, these hit not only GAAP book values, but also reported earnings.
For its structured securitizations, like those backed by commercial mortgages and other asset-backed securities, the company first makes draconian assumptions about the economy's future, against which it tests its portfolio's viability. Among them: a 10% jobless rate, a 30% drop in commercial real-estate values, a 40% drop in home prices and other economic misery.
As far as straight corporate and real- estate debt goes, the company permanently impairs any security that shows scant prospect of recovering over the next two years. This latter standard is more onerous than those followed by most of the Hartford's competitors, but it is being scrapped for fourth-quarter 2008 results.
All this isn't to say that Hartford Financial is a paragon of financial virtue. It certainly ventured into some dicey areas, including the aforementioned $11.2 billion in commercial mortgage-backed securities, $2.5 billion in subprime debt and $8.4 billion in fixed-income and equity exposure to financial-services companies. But most of its holdings in these securities remain highly rated, even after the rating agencies have finally laid waste to most vintages of similar securities. Likewise, the company's tsunami of charge-offs seems to have peaked in 2008's third quarter, when capital losses reached a sickening $2.2 billion. The Hartford expects fourth-quarter after-tax impairments of $250 million to $400 million.
The collapse of the shares of the Hartford and other life insurers began in earnest in October and worsened in November. With the demise of the credit market, some investors feared the heavy hits on insurers' bond holdings would leave the companies unable to meet their insurance obligations. Another worry was that major sellers of variable annuities would be savaged. Such annuities (Hartford Financial has $124 billion of them outstanding) combine aspects of mutual funds and life insurance. In recent years, amid fierce competition, sellers frequently have offered buyers guaranteed minimum monthly benefits that, Wall Street fears, could be difficult to honor, given the stock market's fall.
If all this weren't enough, a Nov. 11 report by Goldman Sachs analyst Christopher Neczypor sent insurance stocks into free fall. He initiated coverage of the industry by slapping Sells on most major players.
The Hartford led off an industry counterattack at its Dec. 5 Investor Day. No, the company maintained, it has no major capital issues that would stop it from honoring all claims or lead to a credit downgrade of its life-insurance operation. Its property-and-casualty unit had $1.1 billion in excess capital that could be infused into the life company. And the parent company has $2.4 billion in unused credit and contingent-capital facilities that could be downstreamed.
Perhaps most reassuring, executives said they had enjoyed better-than-projected performance on their hedges, thus reducing the impact of tumbling stock prices. Short of a slide in the Standard & Poor's 500 below 700 -- it is now around 800 -- no capital infusions would be necessary.
Certainly, the Hartford's shares aren't riskless. The insurer's normalized earnings power of around $10 a share will remain tantalizingly beyond reach for at least several years without a startling rally in both the U.S. stock and bond markets. But the battered shares could double or even triple in the interim.
CTIC Seeks Strategic Alternative for Italian Facility
http://ih.advfn.com/p.php?pid=nmona&cb=1233903868&article=36129592&symbol=N^CTIC
CTI Seeks Strategic Alternative for Italian Facility
Spin-off would reduce CTI burn rate by $14 million
SEATTLE, Feb. 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has engaged the services of a strategic advisory consulting firm, Adjuvant Global Advisors, LLC, (Adjuvant) to assist in developing strategic options for a partnership, asset divestment or joint venture for Cell Therapeutics Europe Sede Secondaria (CTE), the preclinical drug development arm of CTI, in Bresso, Milan. The move is designed to narrow the focus of CTI's business plan, reducing its burn rate by $14 million as it also maintains the mission and workforce of the Bresso facility.
"As CTI transitions from a research-based operation to a commercial drug company, it has been transferring resources to its U.S. sales and marketing operations," said James A. Bianco, M.D., CEO of CTI. "As we have previously announced, we are refocusing our resources on late-stage and marketed products, and as such, CTI needs to reduce its preclinical operations."
Adjuvant's role will be to seek out a potential buyer or partner for the Bresso facility, with the aim of identifying organizations that want to expand with an intact and integrated preclinical team.
"Bresso is an acquisition opportunity for clinical research organizations or pharmaceutical companies to acquire a productive GLP compliant research and development asset that has a proven track record in advancing molecules from discovery to clinic," said Christina Waters, Ph.D., M.B.A., President, CTE and Systems Medicine LLC.
The Bresso personnel have worked together in oncology for many years and offer fully-integrated services ranging from Target discovery, Lead discovery and optimization, Preclinical development (non-GLP/GLP), along with preclinical activities supporting Clinical development (Phase I - Phase III, and Regulatory (EU/USA). The organization is comprised of approximately 50 experienced Ph.D. scientists, laboratory equipment and facilities. There is also available an existing pipeline of internal drug development projects which range from Phase II compounds to preclinical discovery programs.
In addition, "CTI hopes to continue to work with the Bresso facility on contract project work and support of existing CTI pipeline projects as part of the terms of any acquisition or other business arrangement," Waters concluded.
The Bresso facility was formerly NovusPharma, a spin out of Roche/Boehringer Mannheim, which CTI acquired in 2004.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/.
Sign up for email alerts and get RSS feeds at our Web site, http://www.celltherapeutics.com/investors_news.htm
About Adjuvant Global Advisors, LLC
Adjuvant Global Advisors is a strategic advisory firm serving a global pharmaceutical and biotechnology clientele. Its management team consists of scientific and business development experts with significant operational and transaction experience in the drug discovery and development industry. Adjuvant leverages a global industry network and expertise in regulatory, reimbursement, valuation and financial modeling strategies to rapidly develop strategic partnering and licensing options for clinical and preclinical programs. Adjuvant also advises on the repositioning of secondary assets and the promotion and positioning of novel discovery platforms. The firm maintains offices in Bethesda, MD and San Jose, CA. For more information about Adjuvant Global Advisors, please visit http://www.adjuvant.com/
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties include that the Company may not be successful in identifying or completing a partnership, asset divestiture or joint venture with respect to the Bresso facility, the Company may not be successful in reducing its cash burn rate, the Company continues to have negative cash flow and a significant amount of debt outstanding and will need to raise additional capital to fund its operations; and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
Media Contact: Dan Eramian T: 206.272.4343 C: 206.854.1200 E: http://www.celltherapeutics.com/press_room
Investors Contact: Ed Bell T: 206.272.4345 Lindsey Jesch T: 206.272.4347 F: 206.272.4434 E: http://www.celltherapeutics.com/investors
Adjuvant Contact:
Ravi Kiron, PhD, MBA Managing Director Adjuvant Global Advisors, LLC T: 408.238.3398 C: 650.224.3836 E: http://www.adjuvant.com/
DATASOURCE: Cell Therapeutics, Inc.
CONTACT: Media, Dan Eramian, +1-206-272-4343, Cell, +1-206-854-1200,
, or Investors, Ed Bell, +1-206-272-4345, or Lindsey
Jesch, +1-206-272-4347, Fax, +1-206-272-4434, ; or Ravi
Kiron, PhD, MBA, Managing Director of Adjuvant Global Advisors, LLC,
+1-408-238-3398, Cell, +1-650-224-3836,
Web Site: http://www.celltherapeutics.com/
Raser's Electric 100mpg SUV
Raser's Electric 100mpg SUV
February 5, 2009
http://www.rasertech.com/media/movies/html/fev_jan09.html
*****************************************************************
PG&E Signs Agreement To Purchase Plug-In Hybrid SUVs From Raser Technologies
Thursday 7th, February 2008
http://www.rasertech.com/news/scripts/full-news.php?1202382000
RZ - Raser's Electric 100mpg SUV
Raser's Electric 100mpg SUV
February 5, 2009
http://www.rasertech.com/media/movies/html/fev_jan09.html
*****************************************************************
PG&E Signs Agreement To Purchase Plug-In Hybrid SUVs From Raser Technologies
Thursday 7th, February 2008
http://www.rasertech.com/news/scripts/full-news.php?1202382000
HIG -
Earnings Preview: Hartford Financial Services
http://seekingalpha.com/article/118777-earnings-preview-hartford-financial-services?source=feed
ANPI -
Angiotech's corporate partner, Boston Scientific, submits final modules to FDA for approval of second-generation small vessel and long lesion stents
http://www.stockhouse.com/News/USReleasesDetail.aspx?n=7204017
RZ Announces Video News Update on Its PHEV Project
http://www.finanznachrichten.de/nachrichten-2009-02/13034660-raser-technologies-announces-video-news-update-on-its-phev-project-004.htm
05.02.2009 14:58
Raser Technologies Announces Video News Update on Its PHEV Project
Raser Technologies, Inc. (News) (NYSE: RZ) announced that it released today a video news report updating shareholders and the public on its progress to complete the full-sized SUV plug-in hybrid electric (PHEV) demonstration vehicle incorporating the Company’s Symetron technologies. The Company, working in conjunction with FEV and a yet to be named global auto manufacturer, has completed the integration of the 200 KW Symetron traction motor and 100 KW generator and initial testing of those components.
In the video news report, the Company discusses the bench testing of the Symetron components and the delays in receiving and integrating lithium-ion batteries to complete the demonstration vehicle. The Company announced that it expects to begin road tests of the completed vehicle in March.
”I am very pleased with the progress that Jim Spellman and his team have made towards completing this project,” said Patrick Schwartz, President of Raser. ”We are looking forward to demonstrating the full capabilities of this vehicle, even with the current difficult times in the automotive market.”
The video news report can be viewed in its entirety on the Company’s website: www.rasertech.com.
About Raser Technologies
Raser (NYSE: RZ) is an environmentally focused technology licensing and development company operating in two business segments. Raser’s Power Systems segment is seeking to develop clean, renewable geothermal electric power plants and bottom-cycling operations, incorporating licensed heat transfer technology and Raser’s Symetron™ technology developed internally by its Transportation and Industrial Technology segment. Raser’s Transportation and Industrial Technology segment focuses on extended-range plug-in-hybrid vehicle solutions and using Raser’s Symetron™ technology to improve the torque density and efficiency of the electric motors and drive systems used in electric and hybrid-electric vehicle powertrains and industrial applications.
Cautionary Note Regarding Forward-Looking Statements
This press release and referenced video news release contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, but not limited to, statements regarding: our beliefs about the performance and market applicability of our products; our beliefs about the status and enforceability of the Company's intellectual property; our beliefs about the strength of our existing and potential business relations in the motor industry; our beliefs about the strength and enforceability of our agreements; our beliefs about the performance capabilities of our technology; our beliefs about the capabilities, expertise and intentions of our partners; our ability to hire, train and retain key personnel; our ability to successfully complete field testing of Symetron™ technologies. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the competitive environment and our ability to compete in the industry; the strength of our intellectual property; our inability to attract, train and retain key personnel; and such other risks as identified in our quarterly report on Form 10-Q for the quarter ended September 30, 2008, as filed with the Securities and Exchange Commission, and all subsequent filings. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Contacts:
Raser Technologies, Inc.
Richard Putnam, Investor Relations, 801-765-1200
investorrelations@rasertech.com
or
Hayden Communications, Inc
Cameron Donahue, 651-653-1854
cameron@haydenir.com
or
Public Relations contact: Stern&Co.
Richard Stern, 212-888-0044
richstern@sternco.com
or
Alison Simard, 323-650-7117
arsimard@sternco.com
RZ to Participate in Upcoming Investor Conferences
http://www.finanznachrichten.de/nachrichten-2009-02/13034599-raser-technologies-to-participate-in-upcoming-investor-conferences-004.htm
05.02.2009 14:52
Raser Technologies to Participate in Upcoming Investor Conferences
Raser Technologies, Inc. (News) (NYSE: RZ) announced today that management is scheduled to present at the following upcoming investor conferences:
* Southwest Securities Investor Conference on February 12 at the Hotel Crescent Court, Dallas. This conference is scheduling one-on-one meetings, and those interested in meeting directly with management should contact Brian Luter directly at bluter1@bloomberg.net.
* Roth Capital Partners 21st Annual OC Growth Stock Conference on February 17 at 2 p.m. PT at the Ritz-Carlton, Laguna Niguel, Calif. The presentation will be webcast live and archived on the conference website http://www.wsw.com/webcast/roth20/rz/. Management will also participate in a panel discussion on opportunities in power generation at the Roth conference on February 17 at 10 a.m.
* Kaufman Bros. Green Investor Conference on February 18th at the Langham Hotel, Boston. This conference is scheduling one-on-one meetings, and those interested in meeting directly with management should contact their Kaufman Bros. representative.
* Piper Jaffray Fourth Annual Clean Technology and Renewables Conference on February 19 at 11:30 a.m. ET at the Westin Hotel, New York, NY. The presentation will be webcast live and archived on the conference website http://www.corporate-ir.net/ireye/...zhtml?ticker=RZ&item_id=2082397.
Management will be available for one-on-one meetings during these conferences. Interested attendees may schedule the one-on-one meetings directly with the sponsoring conference representatives.
About Raser Technologies
Raser (NYSE: RZ) is an environmentally focused technology licensing and development company operating in two business segments. Raser’s Power Systems segment is seeking to develop clean, renewable geothermal electric power plants and bottom-cycling operations, incorporating licensed heat transfer technology and Raser’s Symetron™ technology developed internally by its Transportation and Industrial Technology segment. Raser’s Transportation and Industrial Technology segment focuses on extended-range plug-in-hybrid vehicle solutions and using Raser’s award-winning Symetron™ technology to improve the torque density and efficiency of the electric motors and drive systems used in electric and hybrid-electric vehicle powertrains and industrial applications. Further information on Raser may be found at: www.rasertech.com.
Contacts:
Raser Technologies, Inc.
Richard Putnam, Investor Relations, 801-765-1200
investorrelations@rasertech.com
or
Hayden Communications, Inc
Cameron Donahue, 651-653-1854
cameron@haydenir.com
or
Public Relations contact: Stern&Co.
Richard Stern, 212-888-0044
richstern@sternco.com
or
Alison Simard, 323-650-7117
arsimard@sternco.com
Texas Approves $5 Billion to Deliver More Wind Power
http://www.stockhouse.com/News/USReleasesDetail.aspx?n=7203125
Texas Approves $5 Billion to Deliver More Wind Power
Nacel Energy Corp
NCEN | 2/5/2009 7:00:00 AM
WASHINGTON, Feb 05, 2009 /PRNewswire via COMTEX News Network/ --
Back in 2006 when Texas overtook California to lead the nation in wind power few would have predicted the break-neck pace of development that would follow. Today, just three years later, wind turbines generating 8005-megawatts, more than all the turbines spinning in California, Iowa and Minnesota, have outstripped the capacity of the high-voltage grid to move the power from windy west Texas to major cities where it's needed.
But, after a year of laying the groundwork to plan for as much as 18,500-megawatts of wind power, the Texas Public Utility Commission (Texas PUC) handed out rights last Thursday to a total of nine companies to construct $5 billion in new transmission lines.
"We have taken a big step to deliver more wind power to Texas electric customers," Texas PUC Chairman Barry Smitherman said after the decision.
West Texas and the Panhandle are the epicenter of wind development - not only in the State, but also the nation. Wind farm developers routinely hold town meetings encouraging local landowners to sign up for turbines and prosper from today's new "green" energy rush - just as the oil companies before them scrambled to stake claims a generation ago.
John Deere, with its 100 year old ties to rural America providing farm and industrial equipment is one of the largest owners and financiers of wind projects in west Texas. Analysts at Bernstein recently upgraded Deere (NYSE: DE) to outperform.
In the heart of the Texas Panhandle, in Moore, Swisher and Donley Counties, NACEL Energy (OTC Bulletin Board: NCEN) has four wind projects underway totaling 80-megawatts. CNBC Guest Analyst Francis Gaskins has a $4 target on NACEL, which is a small-cap wind only company. NACEL closed yesterday at $1.65.
Another active wind farm developer in the region is Edison International. The huge Southern California utility owns an extensive portfolio of wind farms in west Texas generating more than 200-megawatts. Analysts at Barclays Capital raised their target price on Edison International (NYSE: EIX) to $52.
A Before the Bell(TM) renewable energy update
Before the Bell is a member of the Financial Industry Regulatory Authority, CRD number 2382884
SOURCE Before the Bell
Copyright (C) 2009 PR Newswire. All rights reserved
Texas Approves $5 Billion to Deliver More Wind Power
http://www.stockhouse.com/News/USReleasesDetail.aspx?n=7203125
Texas Approves $5 Billion to Deliver More Wind Power
Nacel Energy Corp
NCEN | 2/5/2009 7:00:00 AM
WASHINGTON, Feb 05, 2009 /PRNewswire via COMTEX News Network/ --
Back in 2006 when Texas overtook California to lead the nation in wind power few would have predicted the break-neck pace of development that would follow. Today, just three years later, wind turbines generating 8005-megawatts, more than all the turbines spinning in California, Iowa and Minnesota, have outstripped the capacity of the high-voltage grid to move the power from windy west Texas to major cities where it's needed.
But, after a year of laying the groundwork to plan for as much as 18,500-megawatts of wind power, the Texas Public Utility Commission (Texas PUC) handed out rights last Thursday to a total of nine companies to construct $5 billion in new transmission lines.
"We have taken a big step to deliver more wind power to Texas electric customers," Texas PUC Chairman Barry Smitherman said after the decision.
West Texas and the Panhandle are the epicenter of wind development - not only in the State, but also the nation. Wind farm developers routinely hold town meetings encouraging local landowners to sign up for turbines and prosper from today's new "green" energy rush - just as the oil companies before them scrambled to stake claims a generation ago.
John Deere, with its 100 year old ties to rural America providing farm and industrial equipment is one of the largest owners and financiers of wind projects in west Texas. Analysts at Bernstein recently upgraded Deere (NYSE: DE) to outperform.
In the heart of the Texas Panhandle, in Moore, Swisher and Donley Counties, NACEL Energy (OTC Bulletin Board: NCEN) has four wind projects underway totaling 80-megawatts. CNBC Guest Analyst Francis Gaskins has a $4 target on NACEL, which is a small-cap wind only company. NACEL closed yesterday at $1.65.
Another active wind farm developer in the region is Edison International. The huge Southern California utility owns an extensive portfolio of wind farms in west Texas generating more than 200-megawatts. Analysts at Barclays Capital raised their target price on Edison International (NYSE: EIX) to $52.
A Before the Bell(TM) renewable energy update
Before the Bell is a member of the Financial Industry Regulatory Authority, CRD number 2382884
SOURCE Before the Bell
Copyright (C) 2009 PR Newswire. All rights reserved
CTIC Special Meeting of Shareholders - February 27,2009
http://ih.advfn.com/p.php?pid=nmona&cb=1233833913&article=36113674&symbol=N^CTIC
Notice of Special Meeting of Shareholders
Friday, February 27, 2009
To Our Shareholders:
The Special Meeting of Shareholders of Cell Therapeutics, Inc. (the “Company”) will be held at 10:00 a.m. Pacific Standard Time (PST), on Friday, February 27, 2009, at 501 Elliott Avenue West, Suite 400, Seattle Washington 98119, for the following purposes:
(1)
Approval of an amendment to our amended and restated articles of incorporation to increase the number of authorized shares from 410,000,000 to 810,000,000 and to increase the number of authorized shares of common stock from 400,000,000 to 800,000,000;
(2)
Approval of an amendment to our amended and restated articles of incorporation to effect a reverse stock split;
(3)
Approval of an amendment to our 2007 Equity Incentive Plan to increase the number of shares available for issuance under the plan by 25,000,000 shares;
(4)
Approval of an amendment to our 2007 Employee Stock Purchase Plan to increase the number of shares available for issuance under the plan by 1,000,000 shares; and
(5)
To transact such other business as may properly come before the meeting and all adjournments and postponements thereof.
All shareholders are invited to attend the meeting. Shareholders of record at the close of business on February 4, 2009, the record date fixed by the board of directors, are entitled to vote at the meeting and all adjournments and postponements thereof. A complete list of shareholders entitled to notice of, and to vote at, the meeting will be open to examination by the shareholders beginning ten (10) days prior to the meeting for any purpose germane to the meeting during normal business hours at the office of the Secretary of the Company at 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119.
CTIC Exchanges 83% of Remaining Convertible Preferred Stock...
http://ih.advfn.com/p.php?pid=nmona&cb=1233833913&article=36110186&symbol=N^CTIC
Cell Therapeutics Exchanges 83% of Remaining Convertible Preferred Stock Into New Non-dividend Bearing, Non-redeemable Convertib
SEATTLE, Feb. 5 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (Nasdaq and MTA: CTIC) announced today that it has issued 6,634 shares of Series F Preferred Stock in exchange for 6,634 shares of CTI's Series A, B and C Convertible Preferred Stock. The exchange constitutes 83% in interest of all series of CTI's Convertible Preferred Stock. Each share of the new Preferred Stock will become convertible into 7,143 shares of CTI's common stock, at a conversion price of $0.14 per common share representing a significant premium to the current market price.
The Series F Preferred Stock cannot become convertible into common stock sooner than April 1, 2009. Additionally, the Company has the ability to redeem all, but not less than all, of the outstanding Series F Preferred Stock for cash when the Volume-Weighted Average Price (VWAP) has exceeded $0.28 for ten previous trading days. The Series F Preferred Stock does not provide a redemption right for the holders as did the Series A, B and C Convertible Preferred Stock, thereby eliminating the possibility that the Company could be required to make involuntary cash redemption payments of approximately $6.6 million on the preferred stock that was exchanged. The Series F Preferred Stock does not bear a fixed dividend rate.
"We are pleased that almost all of the remaining preferred shareholders were willing to trade in their securities and enable CTI to avoid their redemption rights and dividend payments, saving the company approximately $6.6 million over the next 6 months, for a meaningful equity position in the Company upon their conversion into common stock," noted James A. Bianco, M.D., CEO of CTI. "With the prospects for three drug approvals in 2009, we believe they chose to participate based on the price appreciation potential of CTI should we be successful with the approvals this year."
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/.
This press release contains forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. The risks and uncertainties include that the Company's operating expenses continue to exceed its net revenues and the Company will continue to need to raise capital to fund its operating expenses; as well as other risks listed or described from time to time in the Company's most recent filings with the SEC on Forms 10-K, 8-K and 10-Q. Except as required by law, the Company does not intend to update any of the statements in this press release upon further developments.
Media Contact: Dan Eramian T: 206.272.4343 C: 206.854.1200 E: http://www.celltherapeutics.com/press_room
Investors Contact: Ed Bell T: 206.272.4345 Lindsey Jesch Logan T : 206.272.4347 F : 206.272.4434 E: http://www.celltherapeutics.com/investors
DATASOURCE: Cell Therapeutics, Inc.
CONTACT: Media, Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200,
; or Investors, Ed Bell, +1-206-272-4345, or Lindsey Jesch
Logan, +1-206-272-4347, fax, +1-206-272-4434, , all of
Cell Therapeutics, Inc.
Web site: http://www.celltherapeutics.com/
IMO - PDGI/JLL Partners will have to improve pps !
PDGI - "L&K" Investigation
...The transaction is unfair, given that, among other things, the Company's shares traded above $7.00 per share as recently as October 2008, the Company has a book value of over $4.00 per share and at least one analyst had a price target of $6.00 per share before the transaction was announced...
****************************************************************
http://www.stockhouse.com/News/USReleasesDetail.aspx?n=7202094
Levi & Korsinsky, LLP Investigates Breach of Fiduciary Duty by the Board of PharmaNet Development Group, Inc.
NEW YORK, Feb 4, 2009 (GlobeNewswire via COMTEX News Network) --
Levi & Korsinsky ("L&K") is investigating breaches of fiduciary duty and other violations of state law by the board of directors of PharmaNet Development Group, Inc. ("PharmaNet" or the "Company") (NMS:PDGI) arising out of their attempt to sell the Company to JLL Partners. Under the terms of the agreement, shareholders of PharmaNet will receive $5.00 cash for each share of PharmaNet they own for a total transaction value of approximately $100 million. The transaction is unfair, given that, among other things, the Company's shares traded above $7.00 per share as recently as October 2008, the Company has a book value of over $4.00 per share and at least one analyst had a price target of $6.00 per share before the transaction was announced. Also, the sales process the Company conducted was flawed given that, in contravention of their fiduciary duties to maximize shareholder value, the Company's Board agreed to a "no-solicitation" provision and also agreed to a $6 million termination fee which will ensure no superior offer will ever be forthcoming. The proposed acquisition is subject to customary conditions and regulatory approvals.
If you own common stock in PharmaNet and wish to obtain additional information, please contact us at the number listed below or visit http://www.zlk.com/pdgi.html
L&K has experience in prosecuting investor securities litigation and an extensive practice in actions involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Levi & Korsinsky, LLP
Levi & Korsinsky, LLP Eduard Korsinsky, Esq. Juan E. Monteverde, Esq. (212) 363-7500 Fax: (212) 363-7171 www.zlk.com 39 Broadway, Suite 1601 New York, NY 10006
(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.
...co-operate
Continental Fuels, Heartland Oil and Gas, Universal Property Development Combine Operations, Reduce Costs
Date : 12/29/2008 @ 8:00AM
http://ih.advfn.com/p.php?pid=nmona&cb=1233758270&article=34846434&symbol=NO^UPDV
Continental Fuels, Heartland Oil and Gas, Universal Property Development Combine Operations, Reduce Costs
As they prepare for the new year and a new era of business development, Continental Fuels (CNFU.PK), Heartland Oil and Gas (HTOG.PK) and Universal Property Development (UPDV.PK) have combined their operations in order to reduce costs. As a result, Continental Fuels CEO Tim Brink has assumed control of the combined operation.
“We have analyzed the operation from top to bottom and eliminated duplication of effort particularly in upper management and accounting,” reports Brink, now the CEO of the entire group of companies. “We continue to maintain sufficient personnel to operate all of the Heartland wells as well as at the Port of Brownsville and Geer Tank Trucks. In the current economy, particularly in light of the falling price of oil and gas, we have moved aggressively to protect and pursue our business model.” With the cooperation and assistance of its main lender, Sheridan Asset Management, the restructuring will allow Heartland to continue to grow as UPDA’s exploration and production arm and Continental Fuels, Inc. (www.continentalfuels.com) as its trading and marketing subsidiary. As a result, the new management expects to significantly expand shareholder value for the entire UPDA conglomerate.
For more information about Heartland Oil and Gas Corp., please visit www.heartlandoilandgas.net About UPDA Universal Property Development and Acquisition Corporation www.universalpropertydevelopment.com is focused on identifying oil & gas companies with proven energy reserves and innovative alternative energy companies with proven technologies.
Statements contained in this press release that are not based upon current or historical fact are forward-looking in nature. Such forward-looking statements reflect the current views of management with respect to future events and are subject to certain risks, uncertainties, and assumptions. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, or described pursuant to similar expressions.
UPDV / HTOG
Universal Property Development Retains Investment Consultant to Raise Capital in Dubai - Prepares Extensive Drilling Program in Southeastern Kansas
Wednesday February 4, 2009, 9:03 am EST
HOUSTON--(BUSINESS WIRE)--Universal Property Development and Acquisition Corporation (Pink Sheets:UPDV - News) has executed a consulting agreement designed to raise up to $85 million from investors in Dubai and the UAE in order to drill as many as 500 new wells along the natural gas pipeline and gathering system owned by Heartland Oil and Gas Corp. (Pink Sheets:HTOG - News) in Southeastern Kansas.
“This new drilling program will allow us to take advantage of the massive investment we’ve already made in Southeastern Kansas,” remarked Tim Brink, CEO of both Universal and Heartland as well as Continental Fuels Corp. (Pink Sheets:CNFU - News). “We have more than 30 producing wells out there and many miles of pipeline along which we can drill over 100 wells without further expansion. Our new consultant indicates that they are experiencing great interest in this project from their clients in Dubai and the rest of the UAE and, as soon as we can complete the necessary paperwork, we are very confident of great results.”
The contemplated program involves equity investment into a new limited partnership for which Universal will serve as general partner. Once drilling is initiated, it is anticipated that 500 wells can be drilled, completed and connected within 3 years.
Statements contained in this press release that are not based upon current or historical fact are forward-looking in nature. Such forward-looking statements reflect the current views of management with respect to future events and are subject to certain risks, uncertainties, and assumptions. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, or described pursuant to similar expressions.
Contact:
Universal Property Development and Acquisition Corporation
Jack Baker (Investor Relations), 561-630-2977
info@universalpropertydevelopment.com
RZ Significantly Adds to Its Oregon Geothermal Resource
http://www.ariva.de/Raser_Significantly_Adds_to_Its_Oregon_Geothermal_Resource_Holdings_with_37_000_Acres_n2881776
Raser Significantly Adds to Its Oregon Geothermal Resource Holdings with 37,000 Acres
15:30 03.02.09
PROVO, Utah--(BUSINESS WIRE)--
Raser Technologies, Inc. (NYSE: RZ) announced today that it has entered into a long-term lease agreement with private land owners covering 37,000 acres of geothermal resources in Southeastern Oregon. The terms of the lease agreement were not specified, but include surface and other rights necessary to build geothermal power plants. The property includes a number of hot springs and wells that indicate the presence of significant geothermal resources. Working with the University of Utahs Energy and Geoscience Institute, Raser has determined this area is one of the more significantly promising geothermal systems, stated Brent M. Cook, CEO of Raser. We believe this is a vast resource area of mid temperature binary potential.
Well logs of drilling in the area over the last few decades in combination with our work done during the past 13 months in this area reveals heat and flows of geothermal fluids indicating that this is potentially a significant resource for geothermal development, stated Richard Clayton, Rasers Executive Vice President. The land is ideally located in southern Oregon so that the power generated from the resource can be sold into either the Oregon or California renewable energy markets.
About Raser Technologies
Raser (NYSE: RZ) is an environmentally-focused technology licensing and development company operating in two business segments. Rasers Power Systems segment is seeking to develop clean, renewable geothermal electric power plants and bottom-cycling operations, incorporating licensed heat transfer technology and Rasers Symetron technology developed internally by its Transportation and Industrial Technology segment. Rasers Transportation and Industrial Technology segment focuses on extended-range plug-in-hybrid vehicle solutions and using Rasers award-winning Symetron technology to improve the torque density and efficiency of the electric motors and drive systems used in electric and hybrid-electric vehicle powertrains and industrial applications. Further information on Raser may be found at: www.rasertech.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, but not limited to, statements regarding: our beliefs about preliminary drilling results; our beliefs about the potential for geothermal power generation on our leased properties; our belief about our ability to exploit the available geothermal resources; our beliefs about the strength and enforceability of our agreements; our beliefs about our ability to successfully negotiate power purchase agreements; and our beliefs about the geothermal market generally. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the competitive environment and our ability to compete in the industry; our ability to adapt our technology for geothermal applications; our ability to secure necessary permits; the strength of our intellectual property; our ability to attract, train and retain key personnel; and such other risks as identified in our quarterly report on Form 10-Q for the quarter ended September 30, 2008, as filed with the Securities and Exchange Commission, and all subsequent filings.
All forward-looking statements in this press release are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
(c)2007 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.